Small Intestinal Bacterial Overgrowth

Complex MONDO:0400000 Pathograph 9 Gastrointestinal disorders Dysbiosis syndromes

Ask OpenScientist

Ask a research question about Small Intestinal Bacterial Overgrowth. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
8
Phenotypes
9
Pathograph
4
Treatments
7
References
2
Deep Research
⚙

Pathophysiology

5
Small-intestinal defense mechanism failure
Loss of endogenous defenses, including gastric acid secretion, intestinal motility, ileocecal valve integrity, secretory immunoglobulins, and pancreaticobiliary antibacterial activity, permits excessive bacterial colonization of the small intestine.
small intestine link
Downstream
Bacterial overgrowth in small intestine Failure of host and anatomic defenses permits expansion or altered composition of small-intestinal bacteria.
Show evidence (1 reference)
PMID:20572300 SUPPORT Human Clinical
"defence mechanisms for preventing bacterial overgrowth: gastric acid secretion"
Bures et al. identify the endogenous defenses whose disruption predisposes to small-intestinal bacterial overgrowth.
Bacterial overgrowth in small intestine
Increased number or altered composition of bacteria in the small intestine, often with colonic-type microbiota in predisposed patients, creates the upstream state that drives fermentation, bile acid disruption, inflammation, and malabsorption.
small intestine link
Downstream
Bacterial carbohydrate fermentation Overgrown small-intestinal microbes ferment luminal carbohydrates and generate gases and metabolites.
Bile acid deconjugation and fat malabsorption Bacterial bile salt hydrolase activity disrupts conjugated bile acids needed for fat absorption.
LPS-driven mucosal inflammation and barrier dysfunction Bacterial products from overgrowth stimulate mucosal inflammatory responses and epithelial barrier dysfunction.
Show evidence (2 references)
PMID:38798120 SUPPORT Human Clinical
"intestinal stasis, such as surgical alteration of the small bowel or chronic"
ESNM/ANMS practice update confirms SIBO is well-established in stasis conditions.
PMID:35398346 SUPPORT Human Clinical
"The concept of small intestinal bacterial overgrowth (SIBO) arose in the context"
Bushyhead and Quigley confirm the pathophysiological framework of SIBO involving colonic microbiota colonizing the small bowel.
Bacterial carbohydrate fermentation
Overgrown small-intestinal microbes ferment carbohydrates to gases and short-chain fatty acids, contributing to bloating, distension, discomfort, and breath-test hydrogen or methane signals.
bacterial carbohydrate fermentation link
small intestine link
Downstream
Abdominal bloating Luminal gas and metabolites generated by fermentation contribute to abdominal distension and bloating.
Abdominal pain Fermentation-associated distension contributes to abdominal discomfort and pain.
Show evidence (2 references)
PMID:20572300 SUPPORT Human Clinical
"tests are most commonly used for the diagnosis of SIBO using glucose or"
Hydrogen and methane breath testing reflects gas production associated with small-intestinal microbial metabolism after carbohydrate substrates.
PMID:32679220 SUPPORT Human Clinical
"Symptoms traditionally linked to SIBO include"
The clinical symptom pattern supports fermentation-associated bloating and discomfort as important consequences of SIBO.
Bile acid deconjugation and fat malabsorption
Bacterial bile salt hydrolase activity deconjugates primary bile acids in the small intestine, reducing bile-acid digestive function and contributing to fat malabsorption and steatorrhea.
bile acid deconjugation link
small intestine link
Downstream
Steatorrhea Reduced bile-acid function impairs lipid absorption and can produce fatty stools.
Malabsorption Impaired bile-acid digestive function contributes to broader nutrient malabsorption.
Show evidence (2 references)
PMID:38727244 SUPPORT In Vitro
"Bile acid function can be disrupted by the gut microbiota via the"
In vitro modeling of human small-intestinal microbiota supports bile acid deconjugation as a mechanism relevant to SIBO-associated malabsorption.
PMID:32679220 SUPPORT Human Clinical
"Steatorrhea may be seen in"
The AGA review links severe SIBO with steatorrhea, the clinical consequence expected from impaired fat absorption.
LPS-driven mucosal inflammation and barrier dysfunction
Bacterial lipopolysaccharide and other microbial products stimulate innate immune responses at the enterocyte barrier, including TLR4-dependent signaling, mucosal inflammatory cytokines, tight-junction dysfunction, and increased intestinal permeability.
enterocyte link
response to lipopolysaccharide link tight junction assembly link ⚠ ABNORMAL
small intestine link
Downstream
Malabsorption Mucosal inflammation and barrier dysfunction can impair epithelial digestive and absorptive function.
Show evidence (3 references)
PMID:35630404 SUPPORT Human Clinical
"Small intestinal bacterial overgrowth (SIBO) contributes to the formation of an"
Prospective human duodenal-fluid study supports mucosal inflammation as part of SIBO biology.
PMID:35630404 SUPPORT Human Clinical
"There is a high prevalence of all three proinflammatory cytokine levels"
Elevated duodenal-fluid cytokines in SIBO patients support an indigenous proinflammatory mucosal environment.
PMID:23201091 SUPPORT In Vitro
"increase in intestinal TJ permeability was mediated by an increase in enterocyte"
Mechanistic epithelial-barrier evidence supports the LPS-TLR4 link to tight-junction permeability used in the SIBO inflammation node.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Small Intestinal Bacterial Overgrowth Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Digestive 5
Abdominal bloating VERY_FREQUENT Abdominal distention (HP:0003270)
Show evidence (1 reference)
PMID:32679220 SUPPORT Human Clinical
"Symptoms traditionally linked to SIBO include"
AGA expert review identifies bloating as a traditional symptom of SIBO.
Diarrhea FREQUENT Diarrhea (HP:0002014)
Show evidence (2 references)
PMID:38798120 SUPPORT
"is associated with diarrhea and signs of"
ESNM/ANMS update confirms diarrhea as a hallmark feature of SIBO.
PMID:18609165 SUPPORT Human Clinical
"Small intestinal bacterial overgrowth (SIBO) syndrome is characterized in its"
Rana and Bhardwaj confirm diarrhea as a defining feature of florid SIBO.
Malabsorption FREQUENT Malabsorption (HP:0002024)
Show evidence (2 references)
PMID:20572300 SUPPORT Human Clinical
"Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
Bures et al. list malabsorption as a core symptom of SIBO.
PMID:35398346 SUPPORT Human Clinical
"the pathophysiological plausibility that underpins SIBO as a cause"
Bushyhead and Quigley affirm SIBO as a recognized cause of maldigestion and malabsorption.
Steatorrhea OCCASIONAL Steatorrhea (HP:0002570)
Show evidence (1 reference)
PMID:32679220 SUPPORT Human Clinical
"Steatorrhea may be seen in"
AGA expert review identifies steatorrhea in severe SIBO cases.
Malnutrition OCCASIONAL Malnutrition (HP:0004395)
Show evidence (1 reference)
PMID:20572300 SUPPORT Human Clinical
"Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
Bures et al. list malnutrition as a recognized consequence of SIBO.
Metabolism 1
Vitamin B12 deficiency OCCASIONAL Decreased circulating vitamin B12 concentration (HP:0100502)
Show evidence (1 reference)
PMID:32679220 SUPPORT Human Clinical
"and, less commonly, vitamin B-12 deficiency, or other nutritional deficiencies"
AGA expert review confirms vitamin B12 deficiency as a recognized laboratory finding in SIBO.
Constitutional 1
Abdominal pain FREQUENT Abdominal pain (HP:0002027)
Show evidence (1 reference)
PMID:32679220 SUPPORT Human Clinical
"Symptoms traditionally linked to SIBO include"
AGA expert review lists abdominal pain/discomfort as a traditional SIBO symptom.
Growth 1
Weight loss OCCASIONAL Weight loss (HP:0001824)
Show evidence (2 references)
PMID:20572300 SUPPORT Human Clinical
"Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
Bures et al. review identifies weight loss as a core SIBO symptom.
PMID:18609165 SUPPORT Human Clinical
"Small intestinal bacterial overgrowth (SIBO) syndrome is characterized in its"
Rana and Bhardwaj confirm weight loss as characteristic of florid SIBO syndrome.
💊

Treatments

4
Antibiotic therapy
Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620
Agent: rifaximin ↗
Rifaximin is the most studied antibiotic for SIBO eradication, with meta-analytic evidence supporting its efficacy and safety.
Show evidence (2 references)
PMID:28078798 SUPPORT Human Clinical
"eradication rate according to intention-to-treat analysis was 70.8% (95% CI"
Meta-analysis of 32 studies shows rifaximin achieves approximately 71% SIBO eradication rate.
PMID:32679220 SUPPORT Human Clinical
"should focus on the identification and correction (where possible) of underlying"
AGA expert review recommends antibiotics as part of SIBO management alongside addressing underlying causes.
Dietary modification
Action: dietary intervention MAXO:0000088
Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.
Prokinetic agents
Action: Pharmacotherapy NCIT:C15986
Medications to improve intestinal motility and reduce stasis.
Nutritional support
Action: supportive care MAXO:0000950
Correction of nutritional deficiencies including vitamin B12, fat-soluble vitamins, and other micronutrients depleted by bacterial overgrowth.
Show evidence (1 reference)
PMID:20572300 SUPPORT Human Clinical
"underlying disease, nutritional support and cyclical gastro-intestinal selective"
Bures et al. recommend nutritional support as a component of comprehensive SIBO therapy.
{ }

Source YAML

click to show 
name: Small Intestinal Bacterial Overgrowth
creation_date: '2025-12-19T01:18:09Z'
updated_date: '2026-05-03T04:43:02Z'
category: Complex
disease_term:
  preferred_term: small intestinal bacterial overgrowth
  term:
    id: MONDO:0400000
    label: small intestinal bacterial overgrowth
parents:
- Gastrointestinal disorders
- Dysbiosis syndromes
pathophysiology:
- name: Small-intestinal defense mechanism failure
  description: >
    Loss of endogenous defenses, including gastric acid secretion, intestinal
    motility, ileocecal valve integrity, secretory immunoglobulins, and
    pancreaticobiliary antibacterial activity, permits excessive bacterial
    colonization of the small intestine.
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Bacterial overgrowth in small intestine
    description: Failure of host and anatomic defenses permits expansion or altered composition of small-intestinal bacteria.
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "defence mechanisms for preventing bacterial overgrowth: gastric acid secretion"
    explanation: Bures et al. identify the endogenous defenses whose disruption predisposes to small-intestinal bacterial overgrowth.
- name: Bacterial overgrowth in small intestine
  description: >
    Increased number or altered composition of bacteria in the small intestine,
    often with colonic-type microbiota in predisposed patients, creates the
    upstream state that drives fermentation, bile acid disruption, inflammation,
    and malabsorption.
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Bacterial carbohydrate fermentation
    description: Overgrown small-intestinal microbes ferment luminal carbohydrates and generate gases and metabolites.
  - target: Bile acid deconjugation and fat malabsorption
    description: Bacterial bile salt hydrolase activity disrupts conjugated bile acids needed for fat absorption.
  - target: LPS-driven mucosal inflammation and barrier dysfunction
    description: Bacterial products from overgrowth stimulate mucosal inflammatory responses and epithelial barrier dysfunction.
  evidence:
  - reference: PMID:38798120
    reference_title: "Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "intestinal stasis, such as surgical alteration of the small bowel or chronic"
    explanation: ESNM/ANMS practice update confirms SIBO is well-established in stasis conditions.
  - reference: PMID:35398346
    reference_title: Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The concept of small intestinal bacterial overgrowth (SIBO) arose in the context"
    explanation: Bushyhead and Quigley confirm the pathophysiological framework of SIBO involving colonic microbiota colonizing the small bowel.
- name: Bacterial carbohydrate fermentation
  description: >
    Overgrown small-intestinal microbes ferment carbohydrates to gases and
    short-chain fatty acids, contributing to bloating, distension, discomfort,
    and breath-test hydrogen or methane signals.
  biological_processes:
  - preferred_term: bacterial carbohydrate fermentation
    term:
      id: GO:0006113
      label: fermentation
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Abdominal bloating
    description: Luminal gas and metabolites generated by fermentation contribute to abdominal distension and bloating.
  - target: Abdominal pain
    description: Fermentation-associated distension contributes to abdominal discomfort and pain.
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "tests are most commonly used for the diagnosis of SIBO using glucose or"
    explanation: Hydrogen and methane breath testing reflects gas production associated with small-intestinal microbial metabolism after carbohydrate substrates.
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms traditionally linked to SIBO include"
    explanation: The clinical symptom pattern supports fermentation-associated bloating and discomfort as important consequences of SIBO.
- name: Bile acid deconjugation and fat malabsorption
  description: >
    Bacterial bile salt hydrolase activity deconjugates primary bile acids in
    the small intestine, reducing bile-acid digestive function and contributing
    to fat malabsorption and steatorrhea.
  biological_processes:
  - preferred_term: bile acid deconjugation
    term:
      id: GO:0008206
      label: bile acid metabolic process
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Steatorrhea
    description: Reduced bile-acid function impairs lipid absorption and can produce fatty stools.
  - target: Malabsorption
    description: Impaired bile-acid digestive function contributes to broader nutrient malabsorption.
  evidence:
  - reference: PMID:38727244
    reference_title: Preservation of conjugated primary bile acids by oxygenation of the small intestinal microbiota in vitro.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Bile acid function can be disrupted by the gut microbiota via the"
    explanation: In vitro modeling of human small-intestinal microbiota supports bile acid deconjugation as a mechanism relevant to SIBO-associated malabsorption.
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Steatorrhea may be seen in"
    explanation: The AGA review links severe SIBO with steatorrhea, the clinical consequence expected from impaired fat absorption.
- name: LPS-driven mucosal inflammation and barrier dysfunction
  description: >
    Bacterial lipopolysaccharide and other microbial products stimulate innate
    immune responses at the enterocyte barrier, including TLR4-dependent
    signaling, mucosal inflammatory cytokines, tight-junction dysfunction, and
    increased intestinal permeability.
  biological_processes:
  - preferred_term: response to lipopolysaccharide
    term:
      id: GO:0032496
      label: response to lipopolysaccharide
  - preferred_term: tight junction assembly
    term:
      id: GO:0070830
      label: bicellular tight junction assembly
    modifier: ABNORMAL
  cell_types:
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  chemical_entities:
  - preferred_term: lipopolysaccharide
    term:
      id: CHEBI:16412
      label: lipopolysaccharide
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Malabsorption
    description: Mucosal inflammation and barrier dysfunction can impair epithelial digestive and absorptive function.
  evidence:
  - reference: PMID:35630404
    reference_title: "Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Small intestinal bacterial overgrowth (SIBO) contributes to the formation of an"
    explanation: Prospective human duodenal-fluid study supports mucosal inflammation as part of SIBO biology.
  - reference: PMID:35630404
    reference_title: "Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a high prevalence of all three proinflammatory cytokine levels"
    explanation: Elevated duodenal-fluid cytokines in SIBO patients support an indigenous proinflammatory mucosal environment.
  - reference: PMID:23201091
    reference_title: Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "increase in intestinal TJ permeability was mediated by an increase in enterocyte"
    explanation: Mechanistic epithelial-barrier evidence supports the LPS-TLR4 link to tight-junction permeability used in the SIBO inflammation node.
phenotypes:
- name: Abdominal bloating
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  description: Distension and discomfort from bacterial fermentation of carbohydrates.
  phenotype_term:
    preferred_term: Abdominal distention
    term:
      id: HP:0003270
      label: Abdominal distention
  evidence:
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms traditionally linked to SIBO include"
    explanation: AGA expert review identifies bloating as a traditional symptom of SIBO.
- name: Diarrhea
  category: Gastrointestinal
  frequency: FREQUENT
  description: Loose stools due to malabsorption and bacterial metabolites.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:38798120
    reference_title: "Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS)."
    supports: SUPPORT
    snippet: "is associated with diarrhea and signs of"
    explanation: ESNM/ANMS update confirms diarrhea as a hallmark feature of SIBO.
  - reference: PMID:18609165
    reference_title: Small intestinal bacterial overgrowth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Small intestinal bacterial overgrowth (SIBO) syndrome is characterized in its"
    explanation: Rana and Bhardwaj confirm diarrhea as a defining feature of florid SIBO.
- name: Malabsorption
  category: Metabolic
  frequency: FREQUENT
  description: Impaired nutrient absorption leading to deficiencies, especially vitamin B12 and fat-soluble vitamins.
  phenotype_term:
    preferred_term: Intestinal malabsorption
    term:
      id: HP:0002024
      label: Malabsorption
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
    explanation: Bures et al. list malabsorption as a core symptom of SIBO.
  - reference: PMID:35398346
    reference_title: Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the pathophysiological plausibility that underpins SIBO as a cause"
    explanation: Bushyhead and Quigley affirm SIBO as a recognized cause of maldigestion and malabsorption.
- name: Abdominal pain
  category: Gastrointestinal
  frequency: FREQUENT
  description: Cramping or discomfort associated with bacterial fermentation and intestinal distension.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms traditionally linked to SIBO include"
    explanation: AGA expert review lists abdominal pain/discomfort as a traditional SIBO symptom.
- name: Vitamin B12 deficiency
  category: Metabolic
  frequency: OCCASIONAL
  description: Bacterial consumption of vitamin B12 in the small intestine leads to host deficiency.
  phenotype_term:
    preferred_term: Vitamin B12 deficiency
    term:
      id: HP:0100502
      label: Decreased circulating vitamin B12 concentration
  evidence:
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and, less commonly, vitamin B-12 deficiency, or other nutritional deficiencies"
    explanation: AGA expert review confirms vitamin B12 deficiency as a recognized laboratory finding in SIBO.
- name: Steatorrhea
  category: Gastrointestinal
  frequency: OCCASIONAL
  description: Fatty stools resulting from bile acid deconjugation by bacteria, impairing fat absorption. Seen in more severe cases.
  phenotype_term:
    preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  evidence:
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Steatorrhea may be seen in"
    explanation: AGA expert review identifies steatorrhea in severe SIBO cases.
- name: Weight loss
  category: Constitutional
  frequency: OCCASIONAL
  description: Unintentional weight loss due to malabsorption and malnutrition from prolonged bacterial overgrowth.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
    explanation: Bures et al. review identifies weight loss as a core SIBO symptom.
  - reference: PMID:18609165
    reference_title: Small intestinal bacterial overgrowth.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Small intestinal bacterial overgrowth (SIBO) syndrome is characterized in its"
    explanation: Rana and Bhardwaj confirm weight loss as characteristic of florid SIBO syndrome.
- name: Malnutrition
  category: Constitutional
  frequency: OCCASIONAL
  description: Nutritional deficiency resulting from chronic malabsorption of macronutrients and micronutrients in the setting of bacterial overgrowth.
  phenotype_term:
    preferred_term: Malnutrition
    term:
      id: HP:0004395
      label: Malnutrition
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms related to SIBO are bloating, diarrhoea, malabsorption, weight loss and"
    explanation: Bures et al. list malnutrition as a recognized consequence of SIBO.
treatments:
- name: Antibiotic therapy
  description: Rifaximin is the most studied antibiotic for SIBO eradication, with meta-analytic evidence supporting its efficacy and safety.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: rifaximin
      term:
        id: CHEBI:75246
        label: rifaximin
  evidence:
  - reference: PMID:28078798
    reference_title: "Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "eradication rate according to intention-to-treat analysis was 70.8% (95% CI"
    explanation: Meta-analysis of 32 studies shows rifaximin achieves approximately 71% SIBO eradication rate.
  - reference: PMID:32679220
    reference_title: "AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "should focus on the identification and correction (where possible) of underlying"
    explanation: AGA expert review recommends antibiotics as part of SIBO management alongside addressing underlying causes.
- name: Dietary modification
  description: Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Prokinetic agents
  description: Medications to improve intestinal motility and reduce stasis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Nutritional support
  description: Correction of nutritional deficiencies including vitamin B12, fat-soluble vitamins, and other micronutrients depleted by bacterial overgrowth.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20572300
    reference_title: Small intestinal bacterial overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "underlying disease, nutritional support and cyclical gastro-intestinal selective"
    explanation: Bures et al. recommend nutritional support as a component of comprehensive SIBO therapy.
datasets:
references:
- reference: DOI:10.1111/nmo.14817
  title: 'Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS)'
  findings: []
- reference: DOI:10.12775/qs.2024.36.56729
  title: 'Small Intestinal Bacterial Overgrowth Syndrome: New Clinical Insights for Multimorbid and High-Risk Patients'
  findings: []
- reference: DOI:10.20944/preprints202403.1571.v1
  title: Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Diseases Related- Current State of Knowledge
  findings: []
- reference: DOI:10.20944/preprints202504.0613.v2
  title: Confusion in Breath Test for Diagnosing Bacterial Overgrowth in the Small Intestine
  findings: []
- reference: DOI:10.3389/fmed.2024.1490506
  title: 'Prevalence and predictors of small intestinal bacterial overgrowth in inflammatory bowel disease: a meta-analysis'
  findings: []
- reference: DOI:10.3748/wjg.v29.i22.3400
  title: Epidemiology of small intestinal bacterial overgrowth
  findings: []
- reference: DOI:10.5056/jnm22168
  title: 'Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis'
  findings: []
📚

References & Deep Research

References

7
DOI:10.1111/nmo.14817
Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS)
No top-level findings curated for this source.
DOI:10.12775/qs.2024.36.56729
Small Intestinal Bacterial Overgrowth Syndrome: New Clinical Insights for Multimorbid and High-Risk Patients
No top-level findings curated for this source.
DOI:10.20944/preprints202403.1571.v1
Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Diseases Related- Current State of Knowledge
No top-level findings curated for this source.
DOI:10.20944/preprints202504.0613.v2
Confusion in Breath Test for Diagnosing Bacterial Overgrowth in the Small Intestine
No top-level findings curated for this source.
DOI:10.3389/fmed.2024.1490506
Prevalence and predictors of small intestinal bacterial overgrowth in inflammatory bowel disease: a meta-analysis
No top-level findings curated for this source.
DOI:10.3748/wjg.v29.i22.3400
Epidemiology of small intestinal bacterial overgrowth
No top-level findings curated for this source.
DOI:10.5056/jnm22168
Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Small Intestinal Bacterial Overgrowth
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 9

Key Pathophysiology Nodes

  • Bacterial overgrowth in small intestine
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1111/nmo.14817
  • DOI:10.12775/qs.2024.36.56729
  • DOI:10.20944/preprints202403.1571.v1
  • DOI:10.20944/preprints202504.0613.v2
  • DOI:10.3389/fmed.2024.1490506
  • DOI:10.3748/wjg.v29.i22.3400
  • DOI:10.5056/jnm22168
Falcon ▸
Pathophysiology description
Edison Scientific Literature 39 citations 2025-12-18T14:13:29.074965

Pathophysiology description SIBO is classically defined as an abnormal increase in the number and/or composition of bacteria in the small intestine, with culture thresholds historically ranging from ≥10^3–10^5 CFU/mL and often cited at ≥10^5 CFU/mL, accompanied by qualitative shifts toward colonic-type taxa and enhanced fermentative metabolism. “Physiologic defenses that normally limit small intestinal colonization include acidic stomach pH, pancreatic enzymes, intestinal immune mechanisms, peristalsis, the ileocecal valve and the mucosal barrier,” such that disruption of gastric acid, motility (including migrating motor complex [MMC]), and the ileocecal barrier promotes overgrowth and malabsorption (URL: https://doi.org/10.20944/preprints202403.1571.v1; posted Mar 26, 2024). Mechanistically, SIBO features increased carbohydrate fermentation (H2, CO2), methanogenesis (CH4) by archaea, short-chain fatty acid production, and bile-acid deconjugation, which together impair digestion/absorption and irritate mucosa. Bacterial products such as lipopolysaccharide (LPS) activate innate receptors (TLR4/TLR2), promoting mucosal inflammation, barrier dysfunction, and—in some settings—endotoxin translocation along the gut–liver axis. Nutrient malabsorption is common, notably vitamin B12 deficiency and fat malabsorption due to bile-acid deconjugation. While SIBO is clearly established in settings of anatomic stasis and dysmotility (e.g., systemic sclerosis), the broader SIBO–IBS hypothesis remains debated, and diagnostic limitations of breath testing have been emphasized by expert groups (ESNM/ANMS) (URL: https://doi.org/10.1111/nmo.14817; May 2024). (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 7-9, kashyap2024criticalappraisalof pages 9-10)

1) Core Pathophysiology - Primary mechanisms - Motility failure and stasis: Impaired small-intestinal motility/MCC (e.g., diabetes autonomic neuropathy, systemic sclerosis), anatomic stasis (surgical blind loops/diverticula, loss of ileocecal valve), and slowed transit permit bacterial accumulation and retrograde colonization. Expert update notes “primary or secondary small intestinal dysmotility,” altered anatomy, increased luminal pH (PPIs/achlorhydria), and loss of antibacterial defenses as core drivers (Neurogastroenterol Motil 2024). (nowakowski2024smallintestinalbacterial pages 4-7, kashyap2024criticalappraisalof pages 9-10) - Hypochlorhydria/PPIs: Reduced gastric acid permits survival of oropharyngeal/colonic bacteria into the small bowel; prolonged PPI use is associated with increased SIBO in observational syntheses (see statistics). (roszkowska2024smallintestinalbacteriala pages 5-7, efremova2023epidemiologyofsmall pages 2-4) - Microbial/metabolic alterations: Overgrowth increases fermentation of carbohydrates to hydrogen, methane, and short-chain fatty acids; bile-salt deconjugation impairs micellar fat absorption. The normal proximal small bowel milieu (bile, low microbial density) restricts “carbohydrate fermentation and bile deconjugation,” but perturbations raise density to 10^7–10^8 CFU/mL and shift composition. (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) - Host barrier and immune responses: LPS and other microbial products induce innate immune activation (TLR2/TLR4), mucosal inflammation, and increased epithelial permeability. “Activation of the immune system and prolonged inflammation… increase intestinal vascular permeability,” with potential for endotoxin-driven signaling and systemic effects. (roszkowska2024smallintestinalbacteriala pages 9-11, roszkowska2024smallintestinalbacteriala pages 7-9) - Dysregulated molecular pathways - Innate immune signaling: LPS–TLR4/TLR2 pathways implicate NF-κB-driven inflammation and barrier disruption. (roszkowska2024smallintestinalbacteriala pages 9-11) - Bile-acid metabolism: Bacterial deconjugation alters BA pool properties and lipid absorption; bile-tolerant taxa can expand under impaired bile secretion (e.g., cirrhosis). (kashyap2024criticalappraisalof pages 9-10) - Fermentation and gas metabolism: Enhanced carbohydrate fermentation; methanogenesis (e.g., Methane-positive profiles linked to constipation phenotypes) and hydrogen production measurable by breath tests. (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) - Affected cellular processes - Tight junction assembly and barrier integrity are compromised by inflammatory signaling and microbial metabolites; brush-border digestive and transport functions are impaired, causing malabsorption. (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7)

2) Key Molecular Players - Genes/Proteins (HGNC) - TLR4 (HGNC:11850) and TLR2 (HGNC:11848): epithelial/immune LPS and bacterial component sensors mediating innate immune activation in SIBO contexts. (roszkowska2024smallintestinalbacteriala pages 9-11) - Secretory IgA (IGHA1/IGHA2): mucosal immune exclusion; reduced function predisposes to SIBO. (kashyap2024criticalappraisalof pages 9-10) - Chemical entities (CHEBI) - Lipopolysaccharide (LPS; CHEBI:16412): triggers TLR signaling; promotes mucosal inflammation and permeability. (roszkowska2024smallintestinalbacteriala pages 9-11) - Bile acids (CHEBI:15889): targets of bacterial deconjugation; altered pool impairs fat absorption. (kashyap2024criticalappraisalof pages 9-10) - Short-chain fatty acids (SCFAs; CHEBI:26666): microbial fermentation products; modulate epithelial/immune responses. (roszkowska2024smallintestinalbacteriala pages 5-7) - Hydrogen (CHEBI:18276) and Methane (CHEBI:16183): gaseous fermentation products measured in breath tests; methane production (methanogen overgrowth) is associated with altered transit. (kashyap2024criticalappraisalof pages 9-10, feng2025prevalenceandpredictors pages 14-14) - Vitamin B12/cobalamin (CHEBI:17697): deficiency from bacterial consumption/competition; macrocytic anemia. (roszkowska2024smallintestinalbacteriala pages 5-7) - Cell types (CL) - Enterocytes (CL:0000584): absorptive epithelium; site of transport and barrier regulation affected in SIBO. (roszkowska2024smallintestinalbacteriala pages 5-7) - Paneth cells (CL:0000587): antimicrobial peptide secretion; part of intrinsic antibacterial defense. (kashyap2024criticalappraisalof pages 9-10) - IgA-producing plasma cells (CL:0000786): mucosal immunity; supports homeostasis. (kashyap2024criticalappraisalof pages 9-10) - Anatomical locations (UBERON) - Small intestine (UBERON:0002108), jejunum (UBERON:0002115), ileum (UBERON:0002116), ileocecal valve (UBERON:0001276). (roszkowska2024smallintestinalbacteriala pages 3-5, roszkowska2024smallintestinalbacteriala pages 5-7)

SIBO molecular/cellular annotations | Category | Name | Ontology ID | Mechanistic role in SIBO (1-2 sentences) | Evidence | |---|---|---:|---|---| | Gene/Protein | TLR4 | HGNC:11850 | Innate receptor recognizing lipopolysaccharide (LPS); activation by bacterial LPS can drive mucosal inflammation and systemic innate signalling contributing to SIBO-associated inflammation. | (roszkowska2024smallintestinalbacteriala pages 9-11, kashyap2024criticalappraisalof pages 9-10) | | Gene/Protein | TLR2 | HGNC:11848 | Pattern-recognition receptor that detects bacterial cell-wall components; contributes to mucosal immune activation and inflammation in response to small-intestinal bacterial products. | (roszkowska2024smallintestinalbacteriala pages 9-11, kashyap2024criticalappraisalof pages 9-10) | | Gene/Protein | IgA (secretory IgA; IGHA1/IGHA2) | IGHA1/IGHA2 (HGNC) | Mucosal antibody that limits bacterial adhesion and colonization in the small intestine; deficiency or impaired IgA responses permit overgrowth and translocation. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) | | Cell Type | Paneth cell | CL:0000587 | Secrete antimicrobial peptides (e.g., defensins) that restrict small-bowel microbial density; dysfunction reduces antimicrobial defenses and promotes overgrowth. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 3-5) | | Cell Type | Enterocyte | CL:0000584 | Main absorptive epithelial cell; site of nutrient absorption and barrier functions (brush border, tight junctions); affected by bacterial metabolites leading to malabsorption and barrier dysfunction. | (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 3-5) | | Cell Type | Plasma cell (IgA-producing) | CL:0000786 | Produces secretory IgA at the mucosa; supports immune exclusion of luminal bacteria and maintenance of small-intestinal homeostasis. | (kashyap2024criticalappraisalof pages 9-10) | | Biological Process (GO) | Bile acid metabolic process | GO:0006631 | Bacterial deconjugation of bile acids alters lipid digestion and fat absorption, promoting fat malabsorption and selection for bile-tolerant taxa in SIBO. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) | | Biological Process (GO) | Carbohydrate fermentation | GO:1900271 | Overgrown small-intestinal fermenters metabolize carbohydrates to gases (H2, CH4) and SCFAs, causing bloating, altered transit, and symptomatic gas production. | (roszkowska2024smallintestinalbacteriala pages 5-7, kashyap2024criticalappraisalof pages 9-10) | | Biological Process (GO) | Response to lipopolysaccharide | GO:0032496 | Enterocyte and immune-cell responses to LPS drive mucosal inflammation and increased permeability, linking microbial overgrowth to immune activation. | (roszkowska2024smallintestinalbacteriala pages 9-11, roszkowska2024smallintestinalbacteriala pages 5-7) | | Biological Process (GO) | Tight junction assembly | GO:0070830 | Regulation and disruption of tight junctions modulate intestinal permeability; bacterial metabolites and inflammation can impair assembly leading to increased translocation. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 9-11) | | Biological Process (GO) | Vitamin B12 transport | GO:0015889 | Disturbance of B12 absorption (bacterial consumption/deconjugation) leads to B12 deficiency and macrocytic anemia in chronic SIBO. | (roszkowska2024smallintestinalbacteriala pages 5-7, feng2025prevalenceandpredictors pages 14-14) | | Cellular Component (GO-CC) | Brush border | GO:0031526 | Apical microvillus domain of enterocytes essential for digestion and absorption; damage or microbial-induced dysfunction contributes to malabsorption in SIBO. | (roszkowska2024smallintestinalbacteriala pages 5-7) | | Cellular Component (GO-CC) | Tight junction | GO:0005923 | Intercellular junctions that maintain epithelial barrier; disruption by bacterial metabolites/inflammation increases permeability and endotoxin translocation. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 9-11) | | Cellular Component (GO-CC) | Extracellular space | GO:0005615 | Lumenal/extracellular compartment where bacterial metabolites (LPS, SCFAs, gases) accumulate and interact with the epithelium. | (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 3-5) | | Anatomical Site (UBERON) | Small intestine | UBERON:0002108 | Primary anatomical location of SIBO; normally low microbial density that, when disrupted by motility, anatomy, or acidity changes, permits overgrowth and malabsorption. | (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 7-9) | | Anatomical Site (UBERON) | Jejunum | UBERON:0002115 | Segment frequently sampled/affected in SIBO where carbohydrate fermentation and nutrient malabsorption commonly occur. | (roszkowska2024smallintestinalbacteriala pages 5-7) | | Anatomical Site (UBERON) | Ileum | UBERON:0002116 | Distal small intestine involved in bile acid and B12 absorption; bacterial deconjugation here promotes bile-acid–mediated malabsorption and B12 deficiency. | (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 9-11) | | Anatomical Site (UBERON) | Ileocecal valve | UBERON:0001276 | Anatomical barrier preventing retrograde colonic bacterial entry; loss or dysfunction permits colon-type bacteria to colonize the small bowel. | (roszkowska2024smallintestinalbacteriala pages 3-5, roszkowska2024smallintestinalbacteriala pages 5-7) | | Chemical Entity (CHEBI) | Lipopolysaccharide (LPS) | CHEBI:16412 | Bacterial endotoxin that activates TLR4/TLR2-driven inflammation and can increase intestinal permeability and systemic endotoxemia. | (roszkowska2024smallintestinalbacteriala pages 9-11, roszkowska2024smallintestinalbacteriala pages 5-7) | | Chemical Entity (CHEBI) | Bile acid | CHEBI:15889 | Substrates for bacterial deconjugation; altered bile acid pool impairs fat digestion and selects for bile-resistant microbes in SIBO. | (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) | | Chemical Entity (CHEBI) | Short-chain fatty acids (SCFAs) | CHEBI:26666 | Microbial metabolites (e.g., acetate, propionate) produced by fermentation; can modulate epithelial function, barrier integrity, and immune responses in SIBO. | (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 3-5) | | Chemical Entity (CHEBI) | Methane | CHEBI:16183 | Product of methanogenic archaea (e.g., Methanobrevibacter) consuming H2; associated with altered transit (constipation-predominant symptoms) in small-intestinal overgrowth contexts. | (feng2025prevalenceandpredictors pages 14-14, roszkowska2024smallintestinalbacteriala pages 5-7) | | Chemical Entity (CHEBI) | Hydrogen | CHEBI:18276 | Gas produced by bacterial fermentation; substrate for methanogenesis and a marker measured in breath tests for SIBO. | (roszkowska2024smallintestinalbacteriala pages 5-7, kashyap2024criticalappraisalof pages 9-10) | | Chemical Entity (CHEBI) | Vitamin B12 (cobalamin) | CHEBI:17697 | Essential micronutrient whose intestinal availability is reduced by bacterial competition/consumption, leading to deficiency-related clinical features in SIBO. | (roszkowska2024smallintestinalbacteriala pages 5-7, feng2025prevalenceandpredictors pages 14-14) |

Table: Concise table mapping genes/proteins, cell types, GO processes, cellular components, anatomical sites, and chemicals implicated in SIBO, with ontology IDs, brief mechanistic roles, and supporting evidence context IDs for use in a disease knowledge base.

3) Biological Processes (GO) disrupted - Carbohydrate fermentation (GO:1900271): excessive fermentation to H2/CH4/SCFAs in small intestine. (roszkowska2024smallintestinalbacteriala pages 5-7, kashyap2024criticalappraisalof pages 9-10) - Bile acid metabolic process (GO:0006631): deconjugation reduces fat absorption and selects for bile-tolerant taxa. (kashyap2024criticalappraisalof pages 9-10) - Response to lipopolysaccharide (GO:0032496): innate activation and mucosal inflammation. (roszkowska2024smallintestinalbacteriala pages 9-11) - Tight junction assembly (GO:0070830) and epithelial barrier establishment (GO:0060627): inflammatory/metabolic disruption increases permeability. (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 9-11) - Vitamin B12 transport (GO:0015889): bacterial competition and mucosal injury reduce B12 availability. (roszkowska2024smallintestinalbacteriala pages 5-7)

4) Cellular Components (GO-CC) - Tight junction (GO:0005923) and brush border (GO:0031526): structural targets of barrier/digestive impairment. (roszkowska2024smallintestinalbacteriala pages 5-7, kashyap2024criticalappraisalof pages 9-10) - Extracellular space (GO:0005615): lumenal compartment where microbial metabolites interact with epithelium. (roszkowska2024smallintestinalbacteriala pages 5-7)

5) Disease Progression (Sequence of events) - Initiation: Predisposing factors (motility disorders with MMC failure, anatomic stasis including loss of ileocecal valve or surgical blind loops, hypochlorhydria/long-term PPI use, impaired bile flow/secretions, and immune deficiency) undermine small-intestinal antibacterial defenses. (nowakowski2024smallintestinalbacterial pages 4-7, kashyap2024criticalappraisalof pages 9-10) - Overgrowth and metabolic shift: Increased bacterial density/compositional shift to fermenters; enhanced carbohydrate fermentation and gas production; bile-salt deconjugation drives fat malabsorption. (kashyap2024criticalappraisalof pages 9-10, roszkowska2024smallintestinalbacteriala pages 5-7) - Epithelial/immune response: LPS and microbial metabolites induce innate (TLR2/TLR4) activation, mucosal inflammation, and tight-junction disruption; increased permeability with potential endotoxin translocation. (roszkowska2024smallintestinalbacteriala pages 9-11, roszkowska2024smallintestinalbacteriala pages 7-9) - Clinical consequences: Malabsorption (vitamin B12 deficiency, fat-soluble vitamin deficiency), steatorrhea, weight loss, anemia; symptom clusters (bloating, pain, diarrhea/constipation). Chronic signaling through the gut–liver axis may contribute to hepatic injury, especially in susceptible hosts. (nowakowski2024smallintestinalbacterial pages 7-9, roszkowska2024smallintestinalbacteriala pages 5-7)

6) Phenotypic Manifestations (HP) with mechanistic links - Abdominal pain (HP:0002027) and abdominal bloating (HP:0003270): due to gas production and luminal distention by fermentation products (H2/CH4/SCFAs). (roszkowska2024smallintestinalbacteriala pages 5-7) - Diarrhea (HP:0002014) and/or constipation (HP:0002019): diarrhea from malabsorption and irritative metabolites; methane-associated slowed transit/constipation patterns in IMO. In SSc, diarrhea is significantly associated with SIBO (OR 5.9; 95% CI 2.9–16.0). (shah2023smallintestinalbacterial pages 5-11) - Steatorrhea (HP:0002570) and weight loss (HP:0001824): bile-salt deconjugation and fat malabsorption with caloric loss. (roszkowska2024smallintestinalbacteriala pages 5-7) - Macrocytic anemia (HP:0001993) from vitamin B12 deficiency; iron deficiency anemia (HP:0001930) from combined malabsorption/inflammation. (nowakowski2024smallintestinalbacterial pages 7-9, roszkowska2024smallintestinalbacteriala pages 5-7) - Failure to thrive in pediatrics (HP:0001508): growth impacts via nutrient malabsorption. (roszkowska2024smallintestinalbacteriala pages 5-7)

Recent developments and latest research (2023–2024 priority) - Expert practice update (ESNM/ANMS, 2024): Provides a critical appraisal of the SIBO hypothesis and cautions on overreliance on breath testing, emphasizing mechanistic heterogeneity (motility, acid suppression, altered bile, immune defenses) and the need for rigorous diagnostics. URL: https://doi.org/10.1111/nmo.14817 (May 2024). (kashyap2024criticalappraisalof pages 9-10) - Broad disease associations (2023): A comprehensive epidemiologic review synthesizes condition-specific SIBO prevalence and risk factors across systemic, hepatic, cardiometabolic, and functional disorders, underscoring heterogeneity and diagnostic variability. URL: https://doi.org/10.3748/wjg.v29.i22.3400 (Jun 14, 2023). (efremova2023epidemiologyofsmall pages 10-12, efremova2023epidemiologyofsmall pages 4-6, efremova2023epidemiologyofsmall pages 2-4) - Systemic sclerosis meta-analysis (2023): High SIBO prevalence in SSc by breath testing and a strong association with diarrhea; rifaximin more effective than rotating antibiotics in subgroup analyses, informing management. URL: https://doi.org/10.5056/jnm22168 (Apr 2023). (shah2023smallintestinalbacterial pages 1-5, shah2023smallintestinalbacterial pages 5-11) - Integrative overviews (2024): Reviews connect SIBO with multiple disease groups and emphasize mechanisms: fermentation, SCFAs, bile deconjugation, LPS/TLR signaling, PPI exposure, and dysmotility/anatomy. URL: https://doi.org/10.20944/preprints202403.1571.v1 (Mar 2024). (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 7-9)

Current applications and real-world implementations - Clinical evaluation: Breath testing (glucose, lactulose) widely used but with recognized limitations and heterogeneity in protocols and interpretation; direct culture remains a reference in select settings. Practice update urges careful test selection and interpretation. (kashyap2024criticalappraisalof pages 9-10) - Therapeutic strategies: Target underlying cause (motility, acid suppression minimization, anatomic issues), antibiotics (e.g., rifaximin), and nutritional correction. Reviews emphasize prokinetics in dysmotility, cautious PPI use, and addressing risk factors in high-risk populations. (roszkowska2024smallintestinalbacteriala pages 7-9, nowakowski2024smallintestinalbacterial pages 7-9)

Expert opinions and analysis (authoritative sources) - ESNM/ANMS clinical practice update (2024) highlights: the “SIBO-IBS hypothesis” spurred research but evidence for broad causality is limited by diagnostic imperfections; mechanistic contributors (dysmotility, bile, pH, immune defenses) should drive individualized evaluation and management. URL: https://doi.org/10.1111/nmo.14817 (May 2024). (kashyap2024criticalappraisalof pages 9-10)

Relevant statistics and data from recent studies - Overall detection in gastroenterology clinic cohorts: ~33.8% by breath testing; IBS pooled prevalence ~31–37% with increased odds vs controls (pooled OR ≈ 3.7). URL: https://doi.org/10.3748/wjg.v29.i22.3400 (Jun 2023). (efremova2023epidemiologyofsmall pages 2-4, efremova2023epidemiologyofsmall pages 12-13) - IBD association (meta-analyses): Pooled prevalence in IBD ~31.0% (95% CI 25.2–37.1) with OR 5.25 (95% CI 2.96–9.32) vs healthy controls; higher in Crohn’s disease (32.2%) than ulcerative colitis (27.8%). URL: https://doi.org/10.3389/fmed.2024.1490506 (Jan 2025, search through Mar 2024). (feng2025prevalenceandpredictors pages 14-14) - Systemic sclerosis: SIBO prevalence ~44.4% by breath test; diarrhea risk increased (OR 5.9). URL: https://doi.org/10.5056/jnm22168 (Apr 2023). (shah2023smallintestinalbacterial pages 5-11, shah2023smallintestinalbacterial pages 1-5) - PPI exposure: Meta-analytic signal for increased SIBO with PPIs (OR 1.71, 95% CI 1.20–2.43), with higher detection after >1 year continuous use; elderly cohorts showed higher breath-test positivity with continuous vs on-demand PPI therapy. URL: https://doi.org/10.3748/wjg.v29.i22.3400 (Jun 2023). (efremova2023epidemiologyofsmall pages 2-4) - Broader risk estimates (preprint synthesis): PPI use associated with OR 7.59 (95% CI 1.81–31.89) vs non-users in selected cohorts; prevalence examples include functional dyspepsia 34.7%, IBS 36.7%, Crohn’s 25.3%, UC 14.3%, cirrhosis up to 51.1%. URL: https://doi.org/10.20944/preprints202504.0613.v2 (Apr 8, 2025). (zhang2025confusioninbreath pages 5-7)

Direct quotes supporting key statements - “SIBO is manifested not only by a quantitative change in microorganisms but also by a qualitative change,” with fermentation generating “hydrogen and methane… [and] short‑chain fatty acids,” and LPS that “can further induce inflammation of enterocytes.” URL: https://doi.org/10.20944/preprints202403.1571.v1 (Mar 26, 2024). (roszkowska2024smallintestinalbacteriala pages 3-5, roszkowska2024smallintestinalbacteriala pages 7-9) - Normal proximal small bowel milieu: “high concentrations of bile which is bacteriostatic… The low microbial density and diversity in the proximal small intestine restricts carbohydrate fermentation and bile deconjugation,” whereas perturbations increase density to “10^7–8 CFU/mL.” URL: https://doi.org/10.1111/nmo.14817 (May 2024). (kashyap2024criticalappraisalof pages 9-10) - Predisposing factors to overgrowth include “altered anatomy… slower small intestinal transit,” “increase in pH due to… proton pump inhibitors,” and “loss of antibacterial defences.” URL: https://doi.org/10.1111/nmo.14817 (May 2024). (kashyap2024criticalappraisalof pages 9-10)

Gene/protein annotations with ontology terms - TLR4 (HGNC:11850): GO:0032496 response to LPS; located at plasma membrane/epithelial and immune cells; role: innate activation and permeability increase in SIBO. (roszkowska2024smallintestinalbacteriala pages 9-11) - TLR2 (HGNC:11848): GO:0032496; role: innate detection of bacterial components in SIBO mucosa. (roszkowska2024smallintestinalbacteriala pages 9-11) - Secretory IgA (IGHA1/2): GO:0006955 immune response; role: immune exclusion—deficiency predisposes to SIBO. (kashyap2024criticalappraisalof pages 9-10)

Cell type involvement (CL terms) - Enterocyte (CL:0000584): barrier and absorption dysfunction. (roszkowska2024smallintestinalbacteriala pages 5-7) - Paneth cell (CL:0000587): antimicrobial defense; dysfunction facilitates overgrowth. (kashyap2024criticalappraisalof pages 9-10) - Plasma cell (CL:0000786): mucosal IgA production. (kashyap2024criticalappraisalof pages 9-10)

Anatomical locations (UBERON terms) - Small intestine (UBERON:0002108); jejunum (UBERON:0002115); ileum (UBERON:0002116); ileocecal valve (UBERON:0001276). (roszkowska2024smallintestinalbacteriala pages 3-5)

Chemical entities (CHEBI terms) - LPS (CHEBI:16412); bile acids (CHEBI:15889); SCFAs (CHEBI:26666); hydrogen (CHEBI:18276); methane (CHEBI:16183); vitamin B12 (CHEBI:17697). (roszkowska2024smallintestinalbacteriala pages 5-7, kashyap2024criticalappraisalof pages 9-10, feng2025prevalenceandpredictors pages 14-14)

Phenotype associations (HP terms) - Abdominal pain (HP:0002027), bloating (HP:0003270), diarrhea (HP:0002014), constipation (HP:0002019), steatorrhea (HP:0002570), weight loss (HP:0001824), macrocytic anemia (HP:0001993), failure to thrive (HP:0001508). (shah2023smallintestinalbacterial pages 5-11, roszkowska2024smallintestinalbacteriala pages 5-7)

Evidence items (PMIDs/DOIs/URLs and dates) - Kashyap et al. Critical appraisal of the SIBO hypothesis and breath testing (ESNM/ANMS). Neurogastroenterol Motil. May 2024. DOI: 10.1111/nmo.14817; URL: https://doi.org/10.1111/nmo.14817. (kashyap2024criticalappraisalof pages 9-10) - Efremova et al. Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol. Jun 14, 2023. DOI: 10.3748/wjg.v29.i22.3400; URL: https://doi.org/10.3748/wjg.v29.i22.3400. (efremova2023epidemiologyofsmall pages 2-4, efremova2023epidemiologyofsmall pages 4-6, efremova2023epidemiologyofsmall pages 12-13) - Shah et al. SIBO complicating GI manifestations of systemic sclerosis: systematic review/meta-analysis. J Neurogastroenterol Motil. Apr 2023. DOI: 10.5056/jnm22168; URL: https://doi.org/10.5056/jnm22168. (shah2023smallintestinalbacterial pages 1-5, shah2023smallintestinalbacterial pages 5-11) - Roszkowska et al. Small intestinal bacterial overgrowth and twelve groups of diseases—current state of knowledge (preprint). Posted Mar 26, 2024. DOI: 10.20944/preprints202403.1571.v1; URL: https://doi.org/10.20944/preprints202403.1571.v1. (roszkowska2024smallintestinalbacteriala pages 5-7, roszkowska2024smallintestinalbacteriala pages 7-9, roszkowska2024smallintestinalbacteriala pages 3-5, roszkowska2024smallintestinalbacteriala pages 9-11) - Nowakowski et al. Small Intestinal Bacterial Overgrowth Syndrome: New Clinical Insights for Multimorbid and High-Risk Patients. Quality in Sport. Dec 2024. DOI: 10.12775/qs.2024.36.56729; URL: https://doi.org/10.12775/qs.2024.36.56729. (nowakowski2024smallintestinalbacterial pages 7-9, nowakowski2024smallintestinalbacterial pages 4-7) - Feng et al. Prevalence and predictors of small intestinal bacterial overgrowth in inflammatory bowel disease: meta-analysis. Frontiers in Medicine. Jan 2025 (search through Mar 2024). DOI: 10.3389/fmed.2024.1490506; URL: https://doi.org/10.3389/fmed.2024.1490506. (feng2025prevalenceandpredictors pages 14-14) - Zhang et al. Confusion in Breath Test for Diagnosing Bacterial Overgrowth in the Small Intestine (preprint). Posted Apr 8, 2025. DOI: 10.20944/preprints202504.0613.v2; URL: https://doi.org/10.20944/preprints202504.0613.v2. (zhang2025confusioninbreath pages 5-7)

Notes on evidence strength and gaps - While mechanistic links (e.g., LPS–TLR signaling, bile-acid deconjugation) are biologically plausible and supported by thematic reviews, high-quality human studies directly connecting these pathways to SIBO clinical outcomes remain limited and confounded by diagnostic heterogeneity. The ESNM/ANMS update encourages careful attribution of symptoms to SIBO and judicious antibiotic use. (kashyap2024criticalappraisalof pages 9-10)

References

  1. (roszkowska2024smallintestinalbacteriala pages 5-7): Paulina Roszkowska, Emilia Klimczak, Ewa Ostrycharz, Aleksandra Rączka, Iwona Wojciechowska-Koszko, Andrzej Dybus, Yeong-Hsiang Cheng, Yu-Hsiang Yu, Szymon Mazgaj, and Beata Hukowska-Szematowicz. Small intestinal bacterial overgrowth (sibo) and twelve groups of diseases related- current state of knowledge. Unknown journal, Mar 2024. URL: https://doi.org/10.20944/preprints202403.1571.v1, doi:10.20944/preprints202403.1571.v1.

  2. (roszkowska2024smallintestinalbacteriala pages 7-9): Paulina Roszkowska, Emilia Klimczak, Ewa Ostrycharz, Aleksandra Rączka, Iwona Wojciechowska-Koszko, Andrzej Dybus, Yeong-Hsiang Cheng, Yu-Hsiang Yu, Szymon Mazgaj, and Beata Hukowska-Szematowicz. Small intestinal bacterial overgrowth (sibo) and twelve groups of diseases related- current state of knowledge. Unknown journal, Mar 2024. URL: https://doi.org/10.20944/preprints202403.1571.v1, doi:10.20944/preprints202403.1571.v1.

  3. (kashyap2024criticalappraisalof pages 9-10): Purna Kashyap, Paul Moayyedi, Eamonn M. M. Quigley, Magnus Simren, and Stephen Vanner. Critical appraisal of the sibo hypothesis and breath testing: a clinical practice update endorsed by the european society of neurogastroenterology and motility (esnm) and the american neurogastroenterology and motility society (anms). Neurogastroenterology & Motility, May 2024. URL: https://doi.org/10.1111/nmo.14817, doi:10.1111/nmo.14817. This article has 48 citations and is from a peer-reviewed journal.

  4. (nowakowski2024smallintestinalbacterial pages 4-7): Krzysztof Nowakowski, Zuzanna Mularczyk, Magdalena Reclik, Piotr Oleksy, and Maciej Tenderenda. Small intestinal bacterial overgrowth syndrome: new clinical insights for multimorbid and high-risk patients. Quality in Sport, 36:56729, Dec 2024. URL: https://doi.org/10.12775/qs.2024.36.56729, doi:10.12775/qs.2024.36.56729. This article has 1 citations.

  5. (efremova2023epidemiologyofsmall pages 2-4): Irina Efremova, Roman Maslennikov, Elena Poluektova, Ekaterina Vasilieva, Yury Zharikov, Andrey Suslov, Yana Letyagina, Evgenii Kozlov, Anna Levshina, and Vladimir Ivashkin. Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29:3400-3421, Jun 2023. URL: https://doi.org/10.3748/wjg.v29.i22.3400, doi:10.3748/wjg.v29.i22.3400. This article has 107 citations and is from a poor quality or predatory journal.

  6. (roszkowska2024smallintestinalbacteriala pages 9-11): Paulina Roszkowska, Emilia Klimczak, Ewa Ostrycharz, Aleksandra Rączka, Iwona Wojciechowska-Koszko, Andrzej Dybus, Yeong-Hsiang Cheng, Yu-Hsiang Yu, Szymon Mazgaj, and Beata Hukowska-Szematowicz. Small intestinal bacterial overgrowth (sibo) and twelve groups of diseases related- current state of knowledge. Unknown journal, Mar 2024. URL: https://doi.org/10.20944/preprints202403.1571.v1, doi:10.20944/preprints202403.1571.v1.

  7. (feng2025prevalenceandpredictors pages 14-14): Xin Feng, Jie Hu, and Xin Zhang. Prevalence and predictors of small intestinal bacterial overgrowth in inflammatory bowel disease: a meta-analysis. Frontiers in Medicine, Jan 2025. URL: https://doi.org/10.3389/fmed.2024.1490506, doi:10.3389/fmed.2024.1490506. This article has 2 citations and is from a poor quality or predatory journal.

  8. (roszkowska2024smallintestinalbacteriala pages 3-5): Paulina Roszkowska, Emilia Klimczak, Ewa Ostrycharz, Aleksandra Rączka, Iwona Wojciechowska-Koszko, Andrzej Dybus, Yeong-Hsiang Cheng, Yu-Hsiang Yu, Szymon Mazgaj, and Beata Hukowska-Szematowicz. Small intestinal bacterial overgrowth (sibo) and twelve groups of diseases related- current state of knowledge. Unknown journal, Mar 2024. URL: https://doi.org/10.20944/preprints202403.1571.v1, doi:10.20944/preprints202403.1571.v1.

  9. (nowakowski2024smallintestinalbacterial pages 7-9): Krzysztof Nowakowski, Zuzanna Mularczyk, Magdalena Reclik, Piotr Oleksy, and Maciej Tenderenda. Small intestinal bacterial overgrowth syndrome: new clinical insights for multimorbid and high-risk patients. Quality in Sport, 36:56729, Dec 2024. URL: https://doi.org/10.12775/qs.2024.36.56729, doi:10.12775/qs.2024.36.56729. This article has 1 citations.

  10. (shah2023smallintestinalbacterial pages 5-11): Ayesha Shah, Veenaa Pakeerathan, Michael P Jones, Purna C Kashyap, Kate Virgo, Thomas Fairlie, Mark Morrison, Uday C Ghoshal, and Gerald J Holtmann. Small intestinal bacterial overgrowth complicating gastrointestinal manifestations of systemic sclerosis: a systematic review and meta-analysis. Journal of Neurogastroenterology and Motility, 29:132-144, Apr 2023. URL: https://doi.org/10.5056/jnm22168, doi:10.5056/jnm22168. This article has 20 citations and is from a peer-reviewed journal.

  11. (efremova2023epidemiologyofsmall pages 10-12): Irina Efremova, Roman Maslennikov, Elena Poluektova, Ekaterina Vasilieva, Yury Zharikov, Andrey Suslov, Yana Letyagina, Evgenii Kozlov, Anna Levshina, and Vladimir Ivashkin. Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29:3400-3421, Jun 2023. URL: https://doi.org/10.3748/wjg.v29.i22.3400, doi:10.3748/wjg.v29.i22.3400. This article has 107 citations and is from a poor quality or predatory journal.

  12. (efremova2023epidemiologyofsmall pages 4-6): Irina Efremova, Roman Maslennikov, Elena Poluektova, Ekaterina Vasilieva, Yury Zharikov, Andrey Suslov, Yana Letyagina, Evgenii Kozlov, Anna Levshina, and Vladimir Ivashkin. Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29:3400-3421, Jun 2023. URL: https://doi.org/10.3748/wjg.v29.i22.3400, doi:10.3748/wjg.v29.i22.3400. This article has 107 citations and is from a poor quality or predatory journal.

  13. (shah2023smallintestinalbacterial pages 1-5): Ayesha Shah, Veenaa Pakeerathan, Michael P Jones, Purna C Kashyap, Kate Virgo, Thomas Fairlie, Mark Morrison, Uday C Ghoshal, and Gerald J Holtmann. Small intestinal bacterial overgrowth complicating gastrointestinal manifestations of systemic sclerosis: a systematic review and meta-analysis. Journal of Neurogastroenterology and Motility, 29:132-144, Apr 2023. URL: https://doi.org/10.5056/jnm22168, doi:10.5056/jnm22168. This article has 20 citations and is from a peer-reviewed journal.

  14. (efremova2023epidemiologyofsmall pages 12-13): Irina Efremova, Roman Maslennikov, Elena Poluektova, Ekaterina Vasilieva, Yury Zharikov, Andrey Suslov, Yana Letyagina, Evgenii Kozlov, Anna Levshina, and Vladimir Ivashkin. Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29:3400-3421, Jun 2023. URL: https://doi.org/10.3748/wjg.v29.i22.3400, doi:10.3748/wjg.v29.i22.3400. This article has 107 citations and is from a poor quality or predatory journal.

  15. (zhang2025confusioninbreath pages 5-7): Yuanyuan Zhang, Pengchun Yang, Caihua Yan, Jing Wang, Xue Ran, Xiaoyan Gao, Gang Lei, Chunmei Ran, Tao Bai, Xiaohua Hou, and Chibing Dai. Confusion in breath test for diagnosing bacterial overgrowth in the small intestine. Apr 2025. URL: https://doi.org/10.20944/preprints202504.0613.v2, doi:10.20944/preprints202504.0613.v2.